In a conference in November 2005 funded by the National Institute of Allergy and Infectious Diseases (NIAID), issues and next steps were discussed related to developing streamlined and improved methods for evaluating cells used to manufacture biological products, including vaccines, for (1) the presence of infectious contaminants and (2) the risks of causing tumors.